Literature DB >> 1306849

Prolactin isoforms secreted by human prolactinomas.

T Hoffmann1, G Gunz, T Brue, P Jaquet, C Ronin.   

Abstract

Prolactin (hPRL) secreted by human prolactinoma cells in culture was purified by gel filtration, lectin affinity chromatography and gel electrophoresis in order to identify the different isoforms of the hormone and to test their respective immunoreactivities and bioactivities. The nonglycosylated hPRL (NG-hPRL), unbound to lectins, was the major form and was a species (NG1-hPRL), of 23,000 (M(r)) apparent molecular weight. The lectin-bound glycosylated hPRL (G-hPRL) consisted of three forms, G1-, G2- and G3-hPRL, of identical molecular weights (25,000 M(r)). Endoglycosidase treatment indicated that these three forms differed by the heterogeneity of their carbohydrate chains. These G-PRLs proved to be 68% less immunoreactive and 50% less bioactive than NG-hPRL. It is concluded from these data that, in prolactinomas, the main variant of the hormone is the nonglycosylated form of PRL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306849     DOI: 10.1159/000182534

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

1.  Secretion of 23 kDa and glycosylated prolactin by rat pituitary cell culture in serum-free media: a comparative morphological, cyto- and immunochemical study.

Authors:  F Bollengier; M Espeel; A Matton; A Mahler; L Vanhaelst
Journal:  Endocrine       Date:  1995-01       Impact factor: 3.633

2.  Bioactivity and glycosylation of circulating prolactin in various physiological and pathological conditions.

Authors:  G M Gambino; P Beck-Peccoz; S Borgato; G Faglia; A Spada; L Persani
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

3.  Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance.

Authors:  T Hoffmann; C Penel; C Ronin
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

Review 4.  Human Pituitary Adenoma Proteomics: New Progresses and Perspectives.

Authors:  Xianquan Zhan; Xiaowei Wang; Tingting Cheng
Journal:  Front Endocrinol (Lausanne)       Date:  2016-05-31       Impact factor: 5.555

5.  The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas.

Authors:  Xianquan Zhan; Dominic M Desiderio
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.